Uppsala, Sweden – January 23, 2026 – As previously communicated, Orexo will announce the Full Year Report 2025 on February 5. The report, which will be published at 7.00 am CET, will focus on the development in the fourth quarter and primarily the impact from the divestment of Zubsolv® US.

On the same day at 2.00 pm, analysts, investors, and media are invited to attend a presentation where CEO Nikolaj Sørensen and CFO Fredrik Järrsten will present, followed by a Q&A.

Participants may access the event via teleconference or audiocast through the following link: https://investorcaller.com/events/orexo/orexo-q4-report-2025

Registration is required to participate. Upon registration, participants will receive the details necessary to join the teleconference. Please note that questions may be asked via the teleconference or submitted through the audiocast.

Prior to the event, the presentation material will be available on the website under Investors/ Report Archive.

For further information contact:
Lena Wange, IR & Communications Director
+46 18 780 88 00, +46 73 064 16 36
ir@orexo.com

About Orexo
Orexo is a Swedish biotechnology company dedicated to advance treatments for severe diseases and life-saving rescue medications to meet future healthcare needs. At the core of our innovation is AmorphOX®, a proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules, enabling new approaches to administration, manufacturing, and distribution. With over 30 years of experience and multiple drugs approved globally, Orexo is advancing a diversified pipeline of programs in clinical and pre-clinical development. The company collaborates with partners in research, development, and commercialization. Headquartered in Uppsala, Sweden, Orexo is listed on Nasdaq Stockholm’s main market and trades as ADRs on the OTCQX market in the United States.

For more information on Orexo, visit www.orexo.com. Follow Orexo on X, LinkedIn, and YouTube.